← Back to headlines
Biogen Acquires Apellis for $5.6B, Expanding C3 Therapies Portfolio
Biogen has agreed to acquire Apellis Pharmaceuticals for approximately $5.6 billion, a deal that will expand Biogen's portfolio of rare-disease and kidney disease medicines by adding C3 therapies. The company is now detailing the deal, projecting mid-to-high-teens growth and EPS accretion by 2027.
31 Mar, 10:58 — 31 Mar, 16:20
The Story
Analyzing sources…
Source Diversity
Source Diversity
High (54/100)5 sources33/33
Spectrum spread— 3/5 buckets covered17/33
Far L
Left2
Left (2)
Yahoocnbc
Center2
Center (2)
marketwatchbloomberg
Right1
Right (1)
seeking-alpha
Far R
Geographic diversity— 1 region4/34
US5
ℹAll sources from US region
Sources
Showing 4 of 5 sources
bloombergHigh19d ago
Biogen to Buy Apellis for $5.6 Billion to Boost Kidney Franchise - Bloomberg.com
Biogen to Buy Apellis for $5.6 Billion to Boost Kidney Franchise Bloomberg.com
Read full article →cnbcMostly Factual19d ago
Biogen to buy Apellis Pharmaceuticals for $5.6 billion to expand its rare disease portfolio
Biogen has agreed to acquire Apellis Pharmaceuticals for about $5.6 billion in cash, expanding its portfolio of rare-disease medicines.
Read full article →marketwatchMostly Factual19d ago
Biogen will acquire a drug company for $5.6 billion to expand work in kidney diseases
Biogen, already developing a drug that can be used to treat several kidney disorders, is paying a large premium for Apellis Pharmaceuticals
By Jaimy Lee
Read full article →YahooMostly Factual19d ago
Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio
Read full article →Coverage Timeline
First report: bloomberg · 31 Mar, 10:58|Full coverage: 5 · 5h|Window: 5h
Left-leaningCenterRight-leaning
